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Abstract
Triple-Negative Breast Cancer (TNBC) is a highly invasive, under-researched subtype of Breast Cancer. Patients lack receptors for
the protein Human Epidermal Growth Factor, and both estrogen and progesterone. This negatively impacts treatment by making
all hormone-sensitive treatments unavailable to TNBC patients. Since the effectiveness of various options has remained understudied, the prognosis remains poor.This paper attempts to analyze and compare the effectiveness of various treatment options.
Because TNBC is very aggressive, the standard approach is to jump in with harsh surgical procedures, including mastectomies and
lumpectomies.This analysis finds that more aggressive treatment may not be necessary to treat all TNBC patients.The addition of
immuno and platinum therapies to traditional chemotherapy appears to increase survival to the same extent as that of mastectomies and lumpectomies. It also appears that radiation therapy greatly enhances treatment and may be an option to avoid a full
radical mastectomy as the survival rates proved to be higher in patients with radiation therapy in conjunction with lumpectomies.
More research is needed; however, aggressive therapies do not need to be the first choice as the other options appear to provide
just as high, if not higher survival rates.
Introduction
Breast cancer is the second leading cause of cancer deaths
and the most common cancer among women.There are an
estimated 281,000 cases of breast cancer amongst women
in 2021. In their lifetime, 1/8 (13%) women will develop
breast cancer, with an estimated 43,000 expected deaths
per year. In contrast, only 1/833 males will develop it over
their lifetime (BreastCancer.org, 2021B, Siegal et al., 2021).
Breast cancer has several different classifications with
regard to the various receptors present on the cells for
hormones that promote their growth, e.g., estrogen and
progesterone.
In healthy breast tissue, these hormones bind to their
receptors and in turn activate and contribute towards
breast tissue formation and growth. In hormone-sensitive breast cancer patients, activation of those receptors
initiates and contributes towards the cancer’s growth.
Treatment options in these patients generally block
those receptors to slow and/or stop the tumor’s growth
(National Cancer Institute, 2021).
Triple-Negative Breast Cancer (TNBC) is a Breast
Cancer subtype in which the patient lacks estrogen, progesterone, and Human Epidermal Growth Factor 2 receptors.This causes treatment options for TNBC patients
to be more limited because hormone therapy generally targets and blocks those receptors to inhibit cancer
growth. Treatment options are generally narrowed down
to surgery, radiation therapy, and chemotherapy. (Center
for Disease Control and Prevention, 2021) This paper will
analyze various available treatments for TNBC and seek
to explore the most effective options.
Methods
This comprehensive review of treatment options for
TNBC was conducted based on the critical analysis of
data collected from PubMed and other databases accessed through Touro College and University System’s
library including ProQuest and EBSCO. Among the
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keywords and phrases used to retrieve data included
“TNBC treatment options,” “TNBC meta-analysis,” and
“TNBC survival rates.”
Genetic Component of TNBC
It has been established that the prognosis of TNBC is
unfavorable due to the lack of treatment options and
low survival rates. A study was aimed to identify the key
genes that could be recognized as biomarkers for TNBC.
Perhaps these biomarkers could promote early identification and potential treatment options for TNBC. The
study identified 194 genes that were actively transcribed
in TNBC patients and repressed in non-TNBC genes/patients. Gene Ontology and Kyoto Encyclopedia of Genes
and Genomes pathway were both used to discover the
biological functions of these genes. The clinical significance of the genes was then examined using the KaplanMeier and Receiver operating characteristic analysis. The
top 20 upregulated and downregulated genes were found
to be expressed consistently in all TNBC vs non-TNBC
patients. Of the identified genes associated with TNBC,
they were all found to be involved in negative regulation
of apoptotic processes, response to drugs, and estradiol. Randomized gene samples were collected from the
cell lines and revealed that the genes ART3, FABP7, and
HORMAD1 were all upregulated in TNBC compared to
non-TNBC tissue. In contrast, TFF1, AGR2, and FOXA1
were downregulated. These genes may serve as key biomarkers and regulators of TNBC (Zhong et al., 2020).
Correlation between TNBC and age:
Studies have found that TNBC is more prevalent
amongst younger patients. In one of them it was found
that of 216 Breast Cancer patients, 52% were ≤ 35, and
of those 19% had TNBC, which consisted of the highest
proportion of the group. Because young women diagnosed with Breast Cancer have a higher correlation to
TNBC, they have a poorer prognosis. Expression of Ki-67,
a protein associated with cell proliferation was also found
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to be higher in the TNBC age ≤ 35 group (Ozisik et al.,
2021).This may help understand why young breast cancer
patients have significantly lower survival rates. One issue
with this study, however, was that there was no statistical
significance found between molecular breast cancer subtypes. This may either be due to their small sample size
or could indicate that age is an independent prognostic
factor in TNBC diagnosis and treatment.
Time Correlation
One study followed TNBC patients over 10 years, and
interestingly enough found that risk and recurrence rates
were not the same throughout the study. In the first five
years following diagnosis, the patients had much higher
death rates, 70% during that time frame. Additionally, the
first five years showed a greater likelihood of recurrence,
whereas those rates were significantly lower in the second five years. No recurrence was found after 8 years.
These results suggest that TNBC patients who survive
longer may have lower risks of death as they age (Dent et
al., 2007). Additionally, these results show us the ambiguity of TNBC. Much research on illness impact, treatment,
and survival is needed to further broaden the approach
towards TNBC.
What is Fueling TNBC Growth
If progesterone, estrogen, and the protein HER-2 are
not fueling TNBC growth, what is? One study found that
phosphatase PTP4A3 was required for TNBC growth in
vitro and in vivo, indicating its role in TNBC development
(Hollander et al., 2016). It has also been found that the
transcription factor c-Myc drives glucose metabolism
in TNBC cells, involving the repression of thioredoxin
interacting protein (TXNIP). This protein is a negative
regulator of glucose uptake and aerobic glycolysis; so, its
repression provides cells methods by which to metabolically fuel themselves and bypass apoptosis. The Mychigh/
TXNIPlow ratio gene signature is correlated with overall
decreased survival and metastatic-free survival in TNBC
patients (Shen et al., 2015).
Treatment Options:
Hormone Receptor-Positive Breast Cancer
Traditional hormone therapy, which is not available for
TNBC patients, works via several methods in which the
interactions between hormone and receptor are blocked.
These include blocking the production of hormones and
blocking hormonal action on tumor cells. Tamoxifen
therapy is one such example that acts as an estrogen
antagonist in estrogen receptor-positive breast cancer
cells. One study revealed that Tamoxifen treatment for 5

years decreased recurrence and death by 41% and 34%,
respectively (Drãgãnescu and Carmocan, 2017). Another
traditional method in treating hormone receptor-positive
breast cancer patients is the use of aromatase inhibitors.
This class of medication blocks the production of the enzyme aromatase, which turns androgenic hormones into
estrogen.This treatment option is used in postmenopausal women because estrogen is primarily inhibited from
being formed from the adrenal glands and other organs
in the body. A study evaluating the impacts of aromatase
inhibitor treatment found that median free survival was
23.8 months for these patients (Tripathy et al., 2018,
Khanna, 2020).
Treatment options for hormone receptor-positive
breast cancer have shown meaningful results. Significant
amounts of patients showed a decreased recurrence,
death, and progression-free survival. In contrast, one
study that followed 1600 patients over a span of 10 years
found that patients with TNBC were more likely to have
died (42 vs 28%) compared to those with other cancers.
Additionally, all deaths of TNBC patients were within 10
years of diagnosis whereas with other cancers patients
lived up to 18 years post-diagnosis. (Dent et al., 2007).
It is apparent that TNBC patients are at a disadvantage
concerning survival rate and prognosis.
Triple-Negative Breast Cancer
Radiation Therapy Combinations
Whole breast radiotherapy and breast-conserving surgery have reduced recurrence rates from 10 to 2%. Postoperative radiation therapy has been shown to drastically
minimize recurrence. A study found that patients who
are treated with a radical mastectomy without radiation
therapy had a significant risk of recurrence compared
to those who received the mastectomy followed by
adjuvant radiation therapy. The study followed 768 patients for over 7.2 years. They were split into 3 groups:
Patients receiving Breast-Conserving therapy (lumpectomy and radiation therapy), Modified radical Mastectomy,
and Modified mastectomy with radiation therapy. These
groups had five-year recurrence-free survival of 94%,
85%, and 87% (P < 0.001). Five-year overall survival was
also measured and was found to be 87%, 82%, and 68%
(P = 0.002). The higher percentage of overall survival in
the Breast-conserving therapy group and modified radical
mastectomy + Radiation therapy group show promising
treatment methods for TNBC patients. Various factors
also impact survival, this includes tumor grade, size, and
status (Abdulkarim et al., 2011).
Discussions regarding radiation treatment post radical
mastectomy have been controversial. However, several
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studies have found that postoperative radiation therapy
following a radical mastectomy, in comparison to patients
only receiving mastectomies, was significantly more efficient with lower recurrence and higher survival rates.
One study found that the recurrence rate for patients
treated with radiation after their mastectomy vs no
post-operative radiation was 11.7% and 25.4%, respectively. The use of radiation therapy significantly lowers recurrence (Abdulkarim et al., 2011). Another study aimed
to compare the effects of both chemotherapy in conjunction with radiation therapy vs chemotherapy alone. The
study involved 681 TNBC patients all of whom received a
mastectomy. The five-year recurrence-free survival rates
were found to be 13.7% higher in the group treated with
both treatments (88.3% vs 74.6%). Additionally, five-year
overall survival was also higher in the group treated with
both (90.4% as opposed to 78.7%) (Wang et al., 2011). It
appears that there is increased improvement in patients
receiving radiation therapy after mastectomy and even
more so with chemotherapy.
Breast Conservation Options
Due to the high-risk, aggressive features of TNBC, concerns regarding surgical approaches to treatment have
been raised. Harsher procedures such as mastectomies
may appear to be a more effective treatment option; however, several studies analyzed this approach in comparison
to those receiving other, less-aggressive operations, such as
lumpectomies, which are done to conserve breast tissue.
One study analyzed TNBC patients who received a
lumpectomy that was followed by reemission, and they
found that of 46 of those patients, 51% subsequentially
had residual invasive disease (Sioshansi et al., 2012).These
rates show that following lumpectomy, TNBC patients
have an elevated risk of residual invasiveness compared
to those with other breast cancer subtypes. The study
suggested that this may be due to the increased tumor
burden associated with TNBC. Lumpectomies alone
therefore do not appear to be as effective.
Researchers have investigated whether a lumpectomy is
as effective as mastectomy in TNBC patients. In another
study of 288 TNBC patients, 111 TNBC patients received
lumpectomy to reserve breast tissue while the rest had a
total mastectomy. The patients in the lumpectomy group
were found to have increased overall survival, (85% vs 81%)
after a 102-month follow-up (P=0.56). These patients also
had an increased rate of disease-free survival at 10 years
(P=0.42) (De-la-Cruz-Ku et al., 2020).These results indicate
that lumpectomy may be more effective in the treatment of
early-stage TNBC; however, more research is needed due
to the lack of statistical significance in these results.
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A meta-analysis of twenty-two studies further followed
whether breast conservation therapy is as effective as a
total mastectomy for treating TNBC patients. This study
found that the TNBC patients who received breast-conserving therapy had lower recurrence and metastasis rates,
as well as a more favorable prognosis (Wang et al., 2013).
Another study compared survival rates of TNBC patients in 2 groups: Lumpectomy patients with radiation
therapy, and mastectomy patients without radiation therapy. The study intended to see if radiation therapy following a lumpectomy could have comparable results to the
mastectomy group. Results were analyzed by comparing
the amount of stromal tumor-infiltrating lymphocytes
(TILs) post-treatment. Higher TILs correspond to greater
amounts of helper and cytotoxic T cells that are present
to fight and destroy tumor cells. In this study of hormone
receptor-positive and negative patients, 46% had TNBC.
In the group with high TILs, the patients who received
lumpectomy followed by radiation therapy had an overall 5-year survival of 100% in comparison to 86% in the
mastectomy group (P = 0.028). This indicates that radiation therapy in conjunction with a lumpectomy may be
a good treatment option for some patients. The groups
with lower TILs however did not have statistically significant survival differences, with survival at 5 years being
86% in the mastectomy and 81% in the lumpectomy with
radiation therapy group (P= 0.241). Although these results show promising options for patients, they cannot be
generalized to all TNBC patients because the study population had a mixture of various breast cancer subtypes
(Mouabbi et al., 2021).
Androgen Receptor Inhibition
A subtype of TNBC has been found and classified to express an androgen receptor. Patients in this group were
found to develop androgen receptor tumors that contribute to their illness. This serves as an additional option for
treatment- including blocking and inactivating the receptors
to reduce cancer growth. In a study aimed to test the use
of androgen receptor antagonists/inhibitors, patients were
treated with enzalutamide. The results found that progression-free and overall survivals were 2.9 and 12.7 months
respectively (Traina et al., 2018). The treatment was tolerated, and this suggests that it may be useful in patients with
this TNBC subtype. It was also found that patients in this
subtype express high levels of PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase), catalytic alpha mutations
and the use of PI3K inhibitors may enhance treatment and
survival; however, more research is needed to explore this
potential option (Lehmann et al., 2014).
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Immunotherapy Option
Immunotherapies with various synthetic treatments aim
to enhance the immune system’s ability to fight the disease.
The use of immunotherapy for TNBC has been largely
analyzed.Tecentriq is one immunotherapeutic that acts as
an “immune checkpoint inhibitor.” Immune checkpoints
serve as regulatory mechanisms in the immune system
to prevent immune responses from being too strong and
inadvertently destroying healthy tissue. Cancer cells often
utilize immune checkpoints to their advantage by shielding them and overcoming identification and destruction
by the immune system.This treatment method utilizes inhibitors that serve to target the checkpoint proteins, enhance the immune systems’ ability to kill cancer cells, and
prevent the metastasis of the cancer cells (BreastCancer.
org, 2021A). A study analyzed the impacts of Tecentriq
along with another traditional chemotherapy, Abraxane,
which is often administered to impede the cancer cells’
ability to grow and divide. (BreastCancer.org, 2020). This
study split the patients into 2 groups; 50% were treated with Abraxane and Tecentriq whereas the other 50%
were administered Abraxane and a placebo. The patients
were followed up for 12.9 months, and it was found that
progression-free survival was greater for patients treated
with the combination (7.2 vs. 5.5 months). Overall survival was also improved in these patients (21.3 vs 17.6
months) (DePolo, J., 2018). This suggests that treatment
and survival may be enhanced with the use of immunotherapy in addition to standard chemotherapy drugs.
Platinum-Based Chemotherapy
Platinum-based chemotherapy is a form of treatment that
utilizes the metallic properties of platinum to destroy rapidly multiplying cells, including cancer cells. These drugs
work by attaching to the DNA of cancer cells. The cell
then works to remove the drug from the DNA; however,
the cell is unable to do so which causes cell death and
prevents the cancer’s growth (University of Nottingham,
2020). Platinum-based treatments appear to be controversial due to their high toxicity rates; however, some
studies have analyzed the implications of platinum-based
chemotherapy in the treatment of TNBC patients. One
study compared and analyzed the impacts of platinum
vs non-platinum-based chemotherapy in TNBC patients.
70% of 495 patients received platinum-based chemotherapy, and of that group, 71% received it as their initial treatment. The overall survival was 19.2 vs 16.8 months for
platinum vs. non-platinum-based treatment (P = 0.439).
These results show that platinum-based chemotherapy
may be impactful in treating TNBC patients; however,
the small sample size and lack of statistical significance

suggest a need for further research.
A meta-analysis (with 2946 patients) of 11 studies
sought to discover platinum implications of patients with
different stages of TNBC. Three of the studies utilized a
platinum drug in combination with the Taxane regimen.
It was found that the patients receiving both platinum
chemotherapy and Taxane responded better compared
to those only receiving Taxane (45 vs 38%, P < 1x10-4).
Another 2 subgroups were compared, with and without
the addition of platinum chemotherapy to the anthracycline regimen, a chemotherapy regimen that includes
usage of compounds that aid in damaging cancer cells’
DNA and preventing their reproduction (BreastCancer.
org, 2012). Here, platinum chemotherapy did not show
any additional benefits in addition to the anthracyclines.
Finally, another 3 studies from the meta-analysis evaluated how platinum chemotherapy impacts the progression-free survival of metastatic TNBC patients. The different rates between the addition of platinum chemotherapy
to the non-platinum were not statistically significant (P
= 0.24), suggesting that platinum drugs may not impact
survival upon metastasis (Pandy et al., 2019). Overall, it
can be concluded that platinum drugs in addition to standard chemotherapy are not one-size-fits-all. Its addition
to some standard chemotherapy regimens has shown to
improve response and survival; however, because several studies had statistically insignificant results, more research is needed.
An additional study aimed to compare the impacts of
platinum-based chemotherapy on TNBC patients that
had lung metastasis. The patients in the platinum group
had sufficiently longer median free survival (10 months
vs 6 months), and also a higher overall survival (32 vs
22 months), with both of these tests giving statistically
significant results (P for both tests < 0.05) (Hong et al.,
2014). This suggests that even patients whose cancer has
metastasized (due to TNBC) can benefit more from the
addition of this treatment.
A major dilemma may be faced by TNBC patients and
oncologists. Is it necessary to approach this disease with
surgical treatments when other options such as immunotherapy and platinum-based chemotherapy appear to
be effective? The answer is complex and would need to
be determined on a patient-by-patient level; however, the
results given above provide evidence that surgical methods in the treatment of TNBC are not necessarily more
effective, and other less invasive/aggressive methods may
be just as promising. The regimens appear to produce a
more favorable prognosis when chemotherapy is used in
conjunction with immuno- and platinum therapy as opposed to the use of chemotherapy alone.
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Conclusion
Treatment options for TNBC patients are limited and
require more research. Many oncologists believe that because TNBC is such an aggressive cancer, harsher treatment options are necessary to remove it, such as surgeries (eg. Mastectomies). As the first line of treatment, this
may not be necessary, because other options including
immuno and platinum chemotherapies are proving to be
as effective. If taking the surgery route, a complete radical
mastectomy is not always needed, because lumpectomies
in conjunction with radiation therapy prove to have very
effective outcomes.The immuno and platinum treatments
with chemotherapy are also showing relatively high survival rates and are comparable to those of surgical approaches. This suggests that TNBC patients may do just
as well with less aggressive treatment options; however,
more research is needed to evaluate the effectiveness
and efficiency of all currently available possibilities.
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